Featured
FDA Approves Groundbreaking Breast Cancer Drug Gedatolisib, Quadrupling Progression-Free Survival in Landmark Trial
The FDA approved gedatolisib (Revtorpyk) on July 14, 2026, as the first comprehensive PI3K/AKT/mTOR pathway inhibitor for HR+/HER2- metastatic breast ...
Read Full Story →